Biosimilars โ cheaper copies of complex biological drugs โ are worth 50 billion globally. Indian companies are racing to capture that market, threatening to cut the price of cancer and.
Audio version coming soon
Biosimilars are the biological equivalent of generic drugs: they copy expensive biologics โ insulin, cancer drugs like trastuzumab (Herceptin), rheumatoid arthritis drugs like adalimumab (Humira) โ once patents expire. The global biosimilar market is worth $27 billion today and growing 25% annually toward a projected $60 billion by 2028. India's pharmaceutical companies โ led by Biocon, Dr. Reddy's, Cipla, and Hetero โ have emerged as world-class biosimilar developers, filing more biosimilar applications with the US FDA than any country except South Korea. In FY26, India's pharma exports crossed $27 billion, with biosimilars the fastest-growing segment at 35% YoY growth. For patients worldwide, India's biosimilar push means life-saving cancer drugs at a fraction of originator prices โ a direct threat to the business model of Roche, AbbVie, and Pfizer.
India's pharmaceutical rise began with a deliberate policy choice: the Patents Act 1970 excluded product patents on drugs, allowing Indian companies to copy branded medicines through reverse engineering. This built the world's largest generic drug manufacturing ecosystem. By 2000, India supplied 20% of global generic drugs by volume, making it the pharmacy of the developing world for essential medicines including anti-retrovirals during the AIDS crisis. The biosimilar era added a third layer of complexity: biologics are manufactured in living cells and cannot be copied by simple chemistry. Indian firms โ starting with Biocon (founded 1978 as an enzyme company) โ invested heavily in bioreactor technology, protein characterisation, and clinical comparison trials. The 2001 Doha Declaration enabled access to life-saving drugs in public health emergencies. And India's strong STEM talent pool โ 1.5 million engineering and science graduates per year โ gave companies the human capital to build world-class R&D labs at a fraction of Western costs.
Unread picks stay on top. Fresh stories may appear as they are ready โ no extra loading.
UnreadIndia now has 12 million obese children under 19, according to ICMR data. School canteens sell junk food while ultra-processed food advertising targets children.
UnreadIndia collects only 11 million units of blood annually against a need of 15 million. The O-negative shortage is acute, urban blood banks run on single-day reserves, and the rural gap is catastrophic.
UnreadIndia has fewer sports medicine doctors than many US college programs. Cricket and marathons grew fast; specialist care did not, so preventable injuries end careers early.
UnreadMicronutrient gaps hit rich and poor: anaemia stays high, vegetarians often lack B12, and urban adults lack vitamin D. Fortification and better diets can bend the curve if delivery improves.
Unread127 essential medicines are out of stock in government hospitals across 12 states. The shortage hits insulin, antibiotics and cancer drugs. Central procurement failure exposes PM Jan Aushadhi gaps.
UnreadIndia averages 6.1 hours of sleep a night, the lowest globally. Sleep deprivation costs India around 7.5 lakh crore rupees in lost productivity each year and drives a silent epidemic of.
India's total pharma exports FY26: $27 billion, up from $16 billion in FY18. Biosimilar segment growth: 35% YoY. Biocon Biologics revenue FY26: approximately $1.4 billion. India's share of global generic drug exports: 20% by volume, 3% by value (the gap reflects commodity prices in generics). US FDA-approved Indian biosimilars: 15+. Price difference โ biosimilar trastuzumab in India vs originator Herceptin in the US: โน18,000 per vial vs $2,500 per vial (roughly 90% cheaper). WHO-PQ certified Indian pharma plants: 500+, the highest of any country. Global biosimilar market 2026: $27 billion; projected 2028: $60 billion. India's pharma sector employs about 2.7 million people directly across manufacturing, R&D, and quality functions.
Myth: Biosimilars are inferior copies. Fact: Regulatory agencies including the US FDA require biosimilars to demonstrate no clinically meaningful difference from the originator in safety and efficacy. Multiple clinical trials โ including studies published in the New England Journal of Medicine โ confirm biosimilar trastuzumab delivers identical breast cancer outcomes to Herceptin. Myth: Indian biosimilars are only for low-income markets. Fact: Biocon's biosimilar insulin and trastuzumab are approved and sold in the United States, Germany, France, and 70+ other countries. They are not a developing-world substitute; they are the same drug at a lower price. Myth: Big Pharma will always maintain its advantage in biologics. Fact: The 2025-2030 patent cliff covers over $180 billion in originator biologic revenue. Every dollar of that is contestable by biosimilar makers โ and Indian companies are the best-positioned manufacturers outside Korea to contest it.
The most direct beneficiaries are cancer patients in middle-income countries who currently cannot afford originator biologics. Trastuzumab โ which treats HER2-positive breast cancer โ costs $70,000+ per year in the US; in India and similar markets, biosimilar versions cost under $3,000 per year. This difference is literally the difference between treatment and death for millions of patients globally. The UK's NHS has saved over ยฃ1 billion in the past five years by switching from originator adalimumab (Humira) to biosimilar versions โ a saving driven largely by Indian and Korean competition. Indian patients benefit too: Biocon's domestic biosimilar insulin price is 30-40% below the originator, improving affordability for India's 77 million diabetics. For the Indian pharmaceutical industry itself, the biosimilar push creates high-value R&D jobs โ biologists, clinical trial managers, regulatory affairs specialists โ that pay significantly above manufacturing-sector averages.
India's biosimilar industry is arguably the most consequential force for global drug access since the AIDS crisis and the Doha Declaration of 2001. The pattern will repeat across oncology biologics through the late 2020s as patent cliffs arrive. Patients in middle-income countries and healthcare systems in the UK and Europe will be the direct beneficiaries. India's pharmaceutical industry faces its biggest opportunity and its biggest challenge in the same decade: the biosimilar patent cliff (2025-2030) will open over $180 billion in originator biologic revenue to generic competition. India's government has responded with the Pharmavision 2047 programme โ a โน21,000 crore PLI scheme for pharma. Long-term competitiveness requires solving the API (active pharmaceutical ingredient) China-dependence problem, since India imports 70% of its APIs from China, creating a strategic vulnerability that biosimilar success cannot fix alone.
Chronology
Follow the arc from background to turning points. On mobile, swipe the cards and use the step rail below; on desktop, use the spine to jump.
India's patent law excludes product patents on drugs, allowing Indian companies to reverse-engineer and manufacture branded drugs without infringing global patents. The generic industry is born.
WTO members declare that TRIPS agreement should not prevent nations from accessing medicines for public health emergencies. India's generic manufacturers become the world's pharmacy for AIDS drugs.
CDSCO issues guidelines for biosimilar approval in India โ the first developing-country regulator to do so. Enables domestic approvals and builds the clinical-trial infrastructure for global filings.
Zydus Cadila's adalimumab biosimilar receives US FDA approval โ the first from an Indian company. Opens the door for other Indian players.
Commerce Ministry data confirms pharma exports of $27 billion in FY26, with biosimilars the fastest-growing segment.
Step 1/5 events
Understand why it happened, how we got here, and what might come next.